Autumn season and difficult cases of allergy sufferers in whom it is worth using ebastine Review article

Main Article Content

Adam J. Sybilski

Abstract

Many environmental factors in autumn and winter increase the severity of allergic rhinitis. To effectively treat allergic symptoms, you need to have an effective and safe second-generation antihistamine in your arsenal. Ebastine is one such drug. It is a prodrug quickly metabolized by the liver to an active metabolite – cerebastine. It is a strong, highly selective histamine H1 receptor antagonist with a prolonged effect. This substance does not exhibit anticholinergic effects. Ebastine is a well-studied second-generation antihistamine with a very good safety and efficacy profile. It is the first-line drug in the treatment of allergic rhinitis and urticaria. Below are four typical cases of patients in whom it is worth using ebastine. Classic patients who may have treatment of allergic diseases with this drug included are: patients requiring higher doses (in the absence of effectiveness of standard doses and severe symptoms of allergic rhinitis or urticaria), patients expecting a quick effect, convenient, easy dosing and taking the drug, and people with coexisting cardiological problems, especially hypertension and heart rhythm disorders. Ebastine has a well-established place in the treatment of allergic rhinitis and urticaria in patients over 12 years of age.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sybilski, A. J. (2024). Autumn season and difficult cases of allergy sufferers in whom it is worth using ebastine. Alergoprofil. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/3159
Section
THERAPY

References

1. Bernstein JA, Bernstein JS, Makol R et al. Allergic Rhinitis: A Review. JAMA. 2024; 331(10): 866-77.
2. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol. 2009; 63(4): 324-30.
3. Wang X, Gao C, Xia Y et al. Effect of Air Pollutants and Meteorological Factors on Daily Outpatient Visits of Allergic Rhinitis in Hohhot, China. J Asthma Allergy. 2023; 16: 1217-28.
4. Takemura M, Inoue D, Takamatsu K et al. Co-existence and seasonal variation in rhinitis and asthma symptoms in patients with asthma. Respir Investig. 2016; 54(5): 320-6.
5. Pawliczak R. Ebastyna – nowy lek przeciwhistaminowy w leczeniu ANN i pokrzywki. Terapia. 2023; 4(423): 16-9.
6. Kupczyk M. Ebastyna w terapii chorób alergicznych. Alergoprofil. 2022; 18(1): 3-7.
7. Muśko M, Sznitowska M. Postacie leków pediatrycznych. Część I. Wymagania i podstawowe problemy – dawkowanie, połykanie, smak. Farm Pol. 2010; 66(3): 215-20.
8. Majos A. Ebastyna. Czym się różni od innych leków przeciwhistaminowych? Terapia. 2024; 4(435): 80-5.
9. Evastix – charakterystyka produktu leczniczego – Rejestr Produktów Leczniczych.
10. Raciborski F, Kłak A, Czarnecka-Operacz M et al. Epidemiology of urticaria in Poland – nationally representative survey results. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2018; 35(1): 67-73.
11. Nowicki RJ, Grubska-Suchanek E, Jahnz-Różyk K et al. Urticaria. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society and the Polish Society of Allergology. Alergologia Polska – Polish Journal of Allergology. 2020; 7(1): 31-9.